Schizophrenia affects roughly one in every hundred people worldwide, and while antipsychotic medications control many of its features, a substantial fraction of patients continue to experience persistent auditory hallucinations, hearing voices that no one else can hear, as well as entrenched negative symptoms such as social withdrawal, emotional flatness, and loss of drive. These residual symptoms are among the most disabling aspects of the illness and are notoriously resistant to pharmacological escalation. This therapeutic gap has fueled decades of interest in brain stimulation techniques that might modulate the dysfunctional neural circuits thought to underlie them, offering hope for patients who have exhausted conventional options.

The technique tested in STIM’Zo belongs to a family of methods known as low-intensity transcranial electrical stimulation. Unlike transcranial magnetic stimulation, which uses rapidly changing magnetic fields to induce currents strong enough to trigger neuronal firing, transcranial electrical stimulation delivers currents so weak, typically on the order of one to two milliamps, that they do not directly cause neurons to discharge. Instead, these faint currents subtly shift the resting electrical potential of cortical neurons, nudging their excitability up or down depending on the stimulation protocol. Transcranial direct current stimulation applies a steady current, whereas tRNS delivers current that fluctuates randomly across a range of frequencies, a design intended to prevent the brain from habituating to a constant signal and to exploit the tendency of neural networks to resonate with stochastic input.

Earlier evidence for tRNS and its close cousin tDCS in schizophrenia rested on a fragile foundation of case reports and small pilot studies, some of which reported striking reductions in hallucination severity. Encouraged by these signals, the STIM’Zo investigators, led by Jerome Brunelin, Marine Mondino, and Emmanuel Poulet and their collaborators, designed a definitive test. The trial was registered as NCT02744989 and received support from the French Ministry of Health, the NeuroDis foundation, and the Centre Scientifique de Monaco, with no funder involvement in the design, analysis, or reporting of the study.

The trial’s methodology reflects the highest standard of clinical rigor. Triple-blind means that patients, the clinicians assessing outcomes, and the statisticians analyzing the data all remained unaware of who received active stimulation and who received sham. The sham condition was engineered to mimic the sensations of real stimulation, typically a brief tingling or itching at the electrode sites at the start of each session, without delivering therapeutic current. Patients were randomized across multiple centers, and the primary outcome was defined in advance as clinical response at Day 5, operationalized as a reduction of at least 25 percent on the total score of the Positive and Negative Syndrome Scale, the most widely used standardized instrument for measuring schizophrenia symptom severity. Secondary outcomes tracked symptoms at one, three, and six months using additional instruments including the Auditory Hallucinations Rating Scale, the Calgary Depression Scale for Schizophrenia, the Clinical Global Impression scale, and a schizophrenia-specific quality of life questionnaire.

The primary analysis included 132 patients, 64 in the active stimulation group and 68 in the sham group, with balanced sex distributions across arms. The result was unambiguous. At Day 5, only 6 of 64 patients in the active group, or 9.4 percent, met the response criterion, compared with 9 of 68 patients, or 13.2 percent, in the sham group. The difference between groups was not statistically significant, with an effect estimate of negative 0.38 and a 95 percent confidence interval spanning negative 1.64 to 0.89, and a p value of 0.56. In plain terms, the sham procedure performed slightly, though not significantly, better than the real intervention. None of the secondary outcomes, measured over the following six months, showed significant differences either, meaning the stimulation neither reduced hallucinations, nor improved negative symptoms, nor lifted mood or quality of life beyond what the placebo ritual itself achieved.

Safety, at least, was not in question. Serious adverse events unrelated to treatment occurred in five patients in the active group and seven in the sham group, a difference that was not statistically significant. The technique was well tolerated, and the trial confirmed that low-intensity electrical stimulation of this kind carries no meaningful physical risk when properly administered. But safety without efficacy is a hollow consolation for patients and clinicians, and the authors’ conclusion was blunt: tRNS did not show superiority over sham in reducing persistent symptoms of schizophrenia.

Why did a technique that showed promise in early studies fail so decisively here? The most instructive answer lies in the trial design itself. Small pilot studies and case reports are exquisitely vulnerable to placebo effects, publication bias, and regression to the mean, and psychiatric symptoms are especially susceptible to the powerful psychological ritual of receiving what feels like an active treatment. The sham group’s 13.2 percent response rate illustrates how much apparent improvement can arise from expectation, attention, and the natural fluctuation of symptoms alone. When these factors are rigorously controlled, as they were in STIM’Zo, the true effect of the intervention can shrink dramatically or vanish. The trial also raises deeper questions about mechanism: whether currents this weak, applied over the scalp and attenuated by skull and skin, can reach and meaningfully alter the deep and distributed circuits implicated in hallucinations remains uncertain. Some researchers argue that stimulation parameters, electrode positioning over regions such as the temporoparietal junction and dorsolateral prefrontal cortex, or the duration of treatment may need optimization, but the STIM’Zo data provide no support for the technique in its current form.

The implications extend well beyond tRNS. The result tempers enthusiasm for a wave of consumer and clinical enthusiasm around electrical brain stimulation for psychiatric conditions, and it underscores the necessity of large, triple-blind, sham-controlled trials before any brain stimulation protocol is adopted into routine care. It also offers a model of how the field should proceed: preregistered endpoints, multicenter recruitment, transparent funding, and honest reporting of negative results. For the patients who participated, and for the millions living with persistent voices and blunted lives, the trial did not deliver a new therapy, but it delivered something arguably just as valuable, a clear and trustworthy answer that redirects research toward approaches with a genuine chance of working. In science, knowing what does not work, and knowing it with confidence, is the first step toward finding what does.

Subject of Research: A triple-blind randomized trial testing transcranial random noise stimulation as an add-on treatment for persistent symptoms in schizophrenia.

Article Title: Low intensity transcranial electrical stimulation for schizophrenia: a triple-blind, randomized, sham-controlled multicenter trial (STIM’Zo)

Article References: Brunelin, J., Mondino, M., Plaze, M., Attal, J., Benoit, M., El-Hage, W., Galvao, F., Haesebaert, J., Jardri, R., Llorca, P. M., Magaud, L., Nathou, C., Szekely, D., Fakra, E., & Poulet, E. (2026). Low intensity transcranial electrical stimulation for schizophrenia: a triple-blind, randomized, sham-controlled multicenter trial (STIM’Zo). BMC Medicine. https://doi.org/10.1186/s12916-026-05227-7

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05227-7

Keywords: schizophrenia, tRNS, brain stimulation, auditory hallucinations, negative symptoms, placebo-controlled trial, BMC Medicine, psychiatry, tDCS, clinical trial, PANSS, noninvasive stimulation

The central idea behind the study is neuromodulation, the deliberate adjustment of nerve activity to change the function of an organ. For the heart, the relevant nerves belong to the autonomic nervous system, the network that operates largely outside conscious control. Sympathetic branches act like an accelerator, speeding the heart when the body demands more oxygen, while parasympathetic branches act as a brake, slowing it during rest and recovery. Clinicians have long known that adjusting this balance can treat rhythm disorders, but the tools available to do so have been crude, invasive, or both. Focused ultrasound offers a way to deliver energy to a precisely defined volume of tissue deep inside the body, stimulating or suppressing neural structures without any incision.

Ultrasound neuromodulation has attracted growing interest over the past decade because sound waves interact with tissue in ways that electrodes cannot. An ultrasound transducer can focus acoustic energy at a target millimeters across, several centimeters beneath the skin, while leaving intervening tissue essentially untouched. The mechanical and thermal effects of the focused beam can alter the excitability of nerve fibers, changing how likely they are to fire action potentials. Depending on the acoustic parameters chosen, the same technology can excite or inhibit neural activity, giving researchers a reversible dial for nervous system function rather than a simple on-off switch.

What distinguishes the new work is the emphasis on image guidance. Delivering energy to the region around the heart is technically demanding because the target moves constantly with each heartbeat and shifts with every breath. The researchers integrated their ultrasound system with imaging that allowed them to track and compensate for this motion, keeping the acoustic focus locked on the intended neural target as the body moved. This kind of closed-loop control is widely regarded as essential if ultrasound neuromodulation is ever to leave the laboratory, because even small targeting errors could disperse the acoustic energy to unintended structures or miss the nerve tissue altogether.

The reported outcome is that this image-guided stimulation could regulate heart rate. By directing focused ultrasound at cardiac neural targets, the team demonstrated that the technique could influence the pace of the heartbeat in a controlled fashion, adjusting the balance between the nerves that accelerate the heart and those that slow it. Regulation, rather than simple stimulation, is the crucial claim. A clinically useful therapy would need to raise or lower heart rate on demand, or damp pathological overactivity, and the study presents its approach as capable of that kind of bidirectional control.

The technical machinery required for this achievement is considerable. High-intensity focused ultrasound systems of the kind used for ablating tumors deliver enough energy to destroy tissue, but neuromodulation typically operates at far lower intensities, below thresholds that would cause lasting damage. The acoustic parameters, including frequency, pulse duration, and repetition rate, determine whether the beam primarily excites nerve fibers, suppresses them, or produces transient heating that changes their behavior. Finding parameter sets that reliably modulate cardiac nerves without harming the surrounding myocardium is one of the field’s central challenges, and the published work contributes data toward that goal.

Why does this matter for medicine? Disturbances of heart rate and rhythm are among the most common and lethal problems in clinical cardiology. Abnormally fast rhythms, abnormally slow rhythms, and chaotic fibrillation all arise from malfunctions in the heart’s electrical control system, and the autonomic nerves that supply the heart are deeply implicated in many of these conditions. Catheter ablation, in which a physician threads wires into the heart and burns small areas of tissue, is effective for some disorders but is invasive and carries procedural risk. Drugs can modulate autonomic tone but act throughout the body, producing side effects far from the heart. A noninvasive, focal, and reversible method for adjusting cardiac nerve activity would fill a genuine gap in the therapeutic arsenal.

The study also speaks to a broader trend in bioelectronic medicine, a field built on the idea that many diseases can be treated by adjusting the electrical signals carried by nerves rather than by delivering chemicals. Researchers have implanted electrodes on the vagus nerve to treat epilepsy and inflammatory conditions, and others have explored stimulation of the carotid sinus and spinal cord for cardiovascular indications. Ultrasound offers these same possibilities from outside the body, which would eliminate implantation surgery and infection risk. The heart, with its well-mapped autonomic innervation and its easily monitored output, is a natural proving ground for the concept, because heart rate itself provides an immediate, continuous readout of whether the neuromodulation is working.

As with any early-stage study, important questions remain before patients could benefit. The durability of the effect, the precise neural structures targeted, the safety margins for repeated sessions, and the translation of results across species are all matters that will require further investigation. The team’s own account presents the work as a demonstration of feasibility: that image guidance can keep a focused ultrasound beam on a moving cardiac target, and that the resulting neuromodulation is sufficient to regulate heart rate. Scaling from demonstration to therapy will demand larger and longer studies, refinement of the targeting algorithms, and careful assessment of any off-target effects on neighboring tissue.

Nevertheless, the publication marks a noteworthy step for a technology that many researchers hope will reshape how medicine interacts with the nervous system. The combination of focused ultrasound with real-time imaging transforms neuromodulation from a procedure requiring precision hardware implanted inside the body into something closer to an examination: the patient lies still, the imaging system tracks the target, and the acoustic beam delivers its influence without a single incision. If subsequent studies confirm and extend these results, the day may come when clinicians tune the heart’s rhythm the way this study did, with sound alone, guided by images, and reversed the moment the therapy ends.

The physics underlying this approach rewards a closer look, because it explains both the promise and the difficulty of the method. Ultrasound waves at the megahertz frequencies typically used for neuromodulation travel through soft tissue at roughly fifteen hundred meters per second and can be steered by phasing the emissions of hundreds of individual elements on a transducer array. Each element fires with a slightly different delay, so that the wavefronts arrive simultaneously at a chosen point, constructive interference concentrates the acoustic pressure there, and tissue elsewhere receives comparatively little energy. This electronic steering means the focus can be repositioned in milliseconds purely by changing the timing signals, a property that pairs naturally with the fast feedback demanded by a beating heart.

The choice of neural target is equally consequential. The heart’s autonomic control is organized around ganglionated plexi, clusters of neurons embedded in the epicardial fat pads near the pulmonary veins, the superior vena cava, and the atria. These microganglia act as local integration centers, relaying and processing signals from the vagus nerve and the sympathetic chain before they reach the cardiac conduction system. Cardiac surgeons and electrophysiologists have known for decades that disturbing these clusters alters atrial rhythm tendencies, which is precisely why they represent attractive targets for noninvasive modulation. Delivering acoustic energy to such small structures, however, requires submillimeter accuracy sustained over many cardiac cycles.

Motion compensation of this kind borrows heavily from techniques developed in radiation oncology, where tumor-tracking linear accelerators adjust beam delivery to a patient’s respiratory cycle. The cardiac problem is harder still, because the heart moves faster than the lungs and exhibits beat-to-beat variability. A successful tracking system must therefore anticipate where the target will be when each acoustic pulse arrives, rather than simply following its past position, and any latency in the imaging chain must be accounted for in the control algorithm.

Safety considerations extend beyond the avoidance of thermal injury. Regulatory frameworks for medical ultrasound, built around indices that estimate heating and the potential for cavitation, will need to be interpreted carefully for a therapy whose intended effect is functional rather than destructive. Repeated exposure of the same neural tissue raises questions about cumulative changes in nerve excitability, and the possibility that acoustic energy scattered by ribs or lung tissue could stimulate unintended structures deserves systematic study. The chest wall itself presents an acoustic obstacle, since bone reflects and absorbs ultrasound strongly, so coupling of the beam through an intercostal window is a practical constraint on positioning.

The experimental logic of using heart rate as an endpoint also deserves emphasis. Unlike modulation of deeper brain circuits, where effects must be inferred indirectly, cardiac neuromodulation produces a continuous, quantitative, beat-by-beat readout that can be captured with noninvasive electrocardiography. This tight feedback loop makes the heart an ideal model system for validating the principles of image-guided acoustic neuromodulation generally, and lessons learned here may well inform applications to the peripheral and central nervous system, where comparable targeting and monitoring challenges await solutions.

Subject of Research: Noninvasive image-guided focused ultrasound neuromodulation of cardiac autonomic nerves to regulate heart rate

Article Title: Image-guided cardiac focused ultrasound neuromodulation regulates heart rate

Article References: Piao, X., Wei, Y., Yao, X., Xu, Z., Pan, J.-J., Hu, P., & Cheng, B. (2026). Image-guided cardiac focused ultrasound neuromodulation regulates heart rate. Communications Engineering. https://doi.org/10.1038/s44172-026-00774-6

Image Credits: AI Generated

DOI: 10.1038/s44172-026-00774-6

Keywords: focused ultrasound, neuromodulation, heart rate, autonomic nervous system, image guidance, cardiology, bioelectronic medicine, ultrasound therapy, cardiac nerves, noninvasive stimulation, Image-guided, cardiac